Focus Partners Advisor Solutions’s Takeda Pharmaceutical TAK Stock Holding History

Focus Partners Advisor Solutions’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Buy	14,302 +4,253	+42%	+$70.4K	﹤0.01%	1120
2026 Q1	$186K	Buy	+10,049	New	+$176K	﹤0.01%	1167
2025 Q3	–	Sell	-10,225	Closed	-$158K	–	1280
2025 Q2	$158K	Buy	+10,225	New	+$151K	﹤0.01%	1041

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Focus Partners Advisor Solutions's TAK Position: Q2 2026 in Review

Focus Partners Advisor Solutions increased its Takeda Pharmaceutical (TAK) stake by 42% in Q2 2026, buying an estimated $70.4K and bringing the position to 14,302 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1120.

Focus Partners Advisor Solutions first reported a position in TAK in Q2 2025 and has held it in 3 quarters since. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Focus Partners Advisor Solutions held 14,302 shares of Takeda Pharmaceutical worth $229K as of Q2 2026.
Focus Partners Advisor Solutions bought 4,253 Takeda Pharmaceutical shares in Q2 2026, an estimated $70.4K.
Takeda Pharmaceutical made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #1120 holding.
Focus Partners Advisor Solutions first reported a position in Takeda Pharmaceutical in Q2 2025 and has held it in 3 quarters since.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.